2025
Hospitalization for COVID-19 and Risk Factors for Severe Disease Among Children: 2022-2024.
Free R, Patel K, Taylor C, Sachdev D, Kawasaki B, Meek J, Openo K, Ryan P, Reeg L, D'Heilly P, Smelser C, Engesser K, Tesini B, Sutton M, Keipp Talbot H, Swain A, Campbell A, Havers F. Hospitalization for COVID-19 and Risk Factors for Severe Disease Among Children: 2022-2024. 2025, 156 PMID: 40604359, DOI: 10.1542/peds.2025-072788.Peer-Reviewed Original ResearchConceptsHospitalized children aged 6Children Aged 6COVID-19-Associated Hospitalization Surveillance NetworkSevere diseaseAged 6Risk factorsAssociated with chronic lung diseaseCOVID-19 vaccineCOVID-19 hospitalizationLaboratory-confirmed SARS-CoV-2 infectionPoisson generalized estimating equationsChronic lung diseaseSARS-CoV-2 infectionChildren Aged 2High-risk conditionsRisk of severe illnessClinical outcomesChronic lungAges 2 to 4Lung diseaseCardiovascular diseaseCOVID-19Severe outcomesSevere illnessMedical conditions
2024
A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
Du Z, Wang L, Bai Y, Liu Y, Lau E, Galvani A, Krug R, Cowling B, Meyers L. A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients. ELife 2024, 13: e89801. PMID: 38622989, PMCID: PMC11078542, DOI: 10.7554/elife.89801.Peer-Reviewed Original ResearchConceptsViral sheddingHospitalized COVID-19 patientsSARS-CoV-2Retrospective cohort studyRisk of reboundCOVID-19 patientsViral reboundTime of treatmentTreated patientsPreventing severe illnessEarly treatmentCohort studyHospitalized patientsPatientsViral replicationReducing infectiousnessSevere illnessTimely treatmentViral dynamicsHealth record dataTreatmentTransmission riskTransmission of SARS-CoV-2EfficacySymptomsGuidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce
Willis Z, Oliveira C, Abzug M, Anosike B, Ardura M, Bio L, Boguniewicz J, Chiotos K, Downes K, Grapentine S, Hersh A, Heston S, Hijano D, Huskins W, James S, Jones S, Lockowitz C, Lloyd E, MacBrayne C, Maron G, McDonough M, Miller C, Morton T, Olivero R, Orscheln R, Schwenk H, Singh P, Soma V, Sue P, Vora S, Nakamura M, Wolf J. Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce. Journal Of The Pediatric Infectious Diseases Society 2024, 13: 159-185. PMID: 38339996, PMCID: PMC11494238, DOI: 10.1093/jpids/piad116.Peer-Reviewed Original ResearchConceptsRisk factorsRisk stratificationPediatric intensive care medicineEffects of therapyNon-hospitalized childrenPediatric infectious diseasesSevere COVID-19Cases of infectionMeta-analysis of dataIntensive care medicineClinical characteristicsPreventive therapyPediatric populationManagement of COVID-19Fatal infectionConsensus statementSevere illnessTherapyMeta-analysisTherapeutic interventionsSARS-CoV-2Expert consensusCare medicineRe-convenedGuidance statements
2023
Transfusion-transmitted Babesia spp.: a changing landscape of epidemiology, regulation, and risk mitigation
Drews S, Kjemtrup A, Krause P, Lambert G, Leiby D, Lewin A, O'Brien S, Renaud C, Tonnetti L, Bloch E. Transfusion-transmitted Babesia spp.: a changing landscape of epidemiology, regulation, and risk mitigation. Journal Of Clinical Microbiology 2023, 61: e01268-22. PMID: 37750699, PMCID: PMC10595070, DOI: 10.1128/jcm.01268-22.Peer-Reviewed Original ResearchConceptsBlood productsWhole blood-derived platelet concentratesNon-endemic areasNon-endemic regionsTTB casesMost patientsRed blood cellsClinical presentationSevere illnessBlood donorsDead-end hostsTick-borne parasitesHuman transmissionEndemic regionsClinical settingEpidemiologyBlood cellsCase numbersPlatelet concentratesTransfusionRiskDeveloping and testing a COVID-19 vaccination acceptance intervention: A pragmatic trial comparing vaccine acceptance intervention vs usual care – Rationale, methods, and implementation
Pyne J, Seal K, Manuel J, DeRonne B, Oliver K, Bertenthal D, Esserman D, Purcell N, Petrakis B, Elwy A. Developing and testing a COVID-19 vaccination acceptance intervention: A pragmatic trial comparing vaccine acceptance intervention vs usual care – Rationale, methods, and implementation. Contemporary Clinical Trials 2023, 133: 107325. PMID: 37652356, DOI: 10.1016/j.cct.2023.107325.Peer-Reviewed Original ResearchVaccination ratesHealthcare providersAcceptance interventionsCOVID-19 vaccine acceptanceOne-year clusterImplementation-effectiveness trialVaccine information sourcesLow vaccination ratesCOVID-19 vaccinationVA healthcare systemHealthcare system approachCOVID-19 vaccinePublic health campaignsMotivational interviewing techniquesGOV IDENTIFIERUsual careVaccine discussionsFuture vaccinationPragmatic trialSevere illnessVaccine acceptanceSignificant disabilityImplementation facilitationVaccination decisionsHealth campaignsThrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin
Chiang K, Gupta A, Sundd P, Krishnamurti L. Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin. Biomedicines 2023, 11: 338. PMID: 36830874, PMCID: PMC9953430, DOI: 10.3390/biomedicines11020338.Peer-Reviewed Original ResearchSickle cell diseaseVaso-occlusive crisisCell diseaseLipid mediatorsCOVID-19Severe SARS-CoV-2 infectionSARS-CoV-2 infectionSevere COVID-19Platelet-leukocyte adhesionAnti-thrombotic agentsThrombo-InflammationEndothelial injuryRespiratory infectionsSevere illnessClinical trialsThromboxane ATherapeutic strategiesTherapeutic targetPotential treatmentPlatelet activationComplement activationGreater riskClinical researchDiseaseEndothelial cells
2022
Genetics, structure, transmission, epidemiology, immune response, and vaccine efficacies of the SARS‐CoV‐2 Delta variant: A comprehensive review
Li H, Arcalas C, Song J, Rahmati M, Park S, Koyanagi A, Lee S, Yon D, Shin J, Smith L. Genetics, structure, transmission, epidemiology, immune response, and vaccine efficacies of the SARS‐CoV‐2 Delta variant: A comprehensive review. Reviews In Medical Virology 2022, 33: e2408. PMID: 36420676, DOI: 10.1002/rmv.2408.Peer-Reviewed Original ResearchConceptsVaccine efficacyDelta variantSARS-CoV-2Enhanced immune escapeLikelihood of severe illnessClinical courseImmune escapeViral loadSevere acute respiratory syndrome coronavirus 2Inflammatory phenotypeAcute respiratory syndrome coronavirus 2ACE-2 receptorRespiratory syndrome coronavirus 2SARS-CoV-2 Delta variantImmune responseSyndrome coronavirus 2Vaccine immunitySevere illnessAntibody neutralisationPredominant variantNarrative reviewVaccineOmicron variantCoronavirus 2Spike proteinAnalysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US
Lang R, Humes E, Coburn SB, Horberg MA, Fathi LF, Watson E, Jefferson CR, Park LS, Gordon KS, Akgün KM, Justice AC, Napravnik S, Edwards JK, Browne LE, Agil DM, Silverberg MJ, Skarbinski J, Leyden WA, Stewart C, Hogan BC, Gebo KA, Marconi VC, Williams CF, Althoff KN. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. JAMA Network Open 2022, 5: e2236397. PMID: 36227594, PMCID: PMC9561947, DOI: 10.1001/jamanetworkopen.2022.36397.Peer-Reviewed Original ResearchConceptsBreakthrough COVID-19Breakthrough infectionsHIV statusCohort studySevere illnessMAIN OUTCOMEBreakthrough SARS-CoV-2 infectionCOVID-19 vaccine typesLow CD4 cell countsSARS-CoV-2 infectionCOVID-19Severe immune suppressionCD4 cell countProportion of patientsCells/μLPrevious COVID-19Additional vaccine dosesProportional hazards modelDiscrete-time proportional hazards modelsRisk reduction recommendationsVaccine guidelinesCD4 cellsCumulative incidenceHazard ratioClinical factorsDemographic and Clinical Characteristics of Antipsychotic Drug-Treated Older Adults with Bipolar Disorder from the Global Aging & Geriatric Experiments in Bipolar Disorder Database (GAGE-BD).
Chen P, Eyler LT, Gildengers A, Beunders AJ, Blumberg HP, Briggs FB, Dols A, Rej S, Forlenza OV, Jimenez E, Mulsant B, Schouws S, Orhan M, Sarna K, Sutherland AN, Vieta E, Tsai S, Yala J, Villa LM, Sajatovic M. Demographic and Clinical Characteristics of Antipsychotic Drug-Treated Older Adults with Bipolar Disorder from the Global Aging & Geriatric Experiments in Bipolar Disorder Database (GAGE-BD). Psychopharmacology Bulletin 2022, 52: 8-33. PMID: 35721813, PMCID: PMC9172555.Peer-Reviewed Original ResearchConceptsOlder age bipolar disorderFirst-generation antipsychoticsAntipsychotic drugsBipolar disorderPsychiatric hospitalizationMean age 63.2 yearsGlobal AGEingClinical characteristicsFrequent hospitalizationsClinical variablesSevere illnessTreatment statusGreater burdenHospitalizationDisorder databaseOlder adultsCross-sectional dataLongitudinal outcomesDisordersPatientsGeneralized mixed modelMultivariate model resultsInternational studiesDrugsObservational analysisImmunopathological changes, complications, sequelae and immunological memory in COVID-19 patients
Yao L, Lu L, Ma W. Immunopathological changes, complications, sequelae and immunological memory in COVID-19 patients. Heliyon 2022, 8: e09302. PMID: 35497026, PMCID: PMC9040416, DOI: 10.1016/j.heliyon.2022.e09302.Peer-Reviewed Original ResearchCOVID-19 patientsSARS-CoV-2Immunological memoryMultiple organsHealth problemsSARS-CoV-2 infectionACE2 protein levelsMultidisciplinary care teamCOVID-19 survivorsLong-term health problemsSARS-CoV-2 virusImmunopathological changesImmunological changesSevere complicationsOrgan failureModerate symptomsSevere illnessCare teamFurther managementLung tissueComplicationsPatientsDisease casesMajor organsReceptors results
2021
Alcohol Use and the Risk of Communicable Diseases
Morojele NK, Shenoi SV, Shuper PA, Braithwaite RS, Rehm J. Alcohol Use and the Risk of Communicable Diseases. Nutrients 2021, 13: 3317. PMID: 34684318, PMCID: PMC8540096, DOI: 10.3390/nu13103317.Peer-Reviewed Original ResearchConceptsCommunicable diseasesTreatment outcomesSevere acute respiratory syndrome coronavirus 2Respiratory infection/pneumoniaAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Alcohol useDisability-adjusted life yearsSyndrome coronavirus 2Poor treatment outcomesCOVID-19 infectionAlcohol use disorderGlobal health concernIndividual-level interventionsDifferent communicable diseasesTB deathsImmunodeficiency virusCoronavirus 2Severe illnessUse disordersPneumoniaHeavy drinkersLife yearsHIV researchTuberculosisMorbidity and Mortality Among Adults Experiencing Homelessness Hospitalized With COVID-19
Cha S, Henry A, Montgomery M, Laws R, Pham H, Wortham J, Garg S, Kim L, Mosites E, Chai S, Kawasaki B, Meek J, Anderson E, Weigel A, Ryan P, Kim S, Como-Sabetti K, Torres S, Muse A, Bennett N, Billing L, Sutton M, Talbot H, Risk I. Morbidity and Mortality Among Adults Experiencing Homelessness Hospitalized With COVID-19. The Journal Of Infectious Diseases 2021, 224: 425-430. PMID: 33993309, PMCID: PMC8194564, DOI: 10.1093/infdis/jiab261.Peer-Reviewed Original ResearchConceptsMechanical ventilationCOVID-19-associated hospitalizationNon-Hispanic black personsCOVID-19Population-based surveillance dataHealth conditionsChronic health conditionsCoronavirus disease 2019ICU admissionClinical characteristicsRespiratory supportClinical outcomesSevere illnessDisease 2019High riskSurveillance dataAdults Experiencing HomelessnessAnalytic sampleEthnic minority groupsHousing statusBlack personsVentilationDeathOutcomesHospitalization
2020
Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2
Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, Yarbrough A, Abzug MJ, MacBrayne CE, Soma VL, Dulek DE, Vora SB, Waghmare A, Wolf J, Olivero R, Grapentine S, Wattier RL, Bio L, Cross SJ, Dillman NO, Downes KJ, Oliveira CR, Timberlake K, Young J, Orscheln RC, Tamma PD, Schwenk HT, Zachariah P, Aldrich ML, Goldman DL, Groves HE, Rajapakse NS, Lamb GS, Tribble AC, Hersh AL, Thorell EA, Denison MR, Ratner AJ, Newland JG, Nakamura MM. Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. Journal Of The Pediatric Infectious Diseases Society 2020, 10: 34-48. PMID: 32918548, PMCID: PMC7543452, DOI: 10.1093/jpids/piaa115.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMechanical ventilationCOVID-19Pediatric infectious disease physiciansInvasive mechanical ventilationSupplemental oxygen requirementInfectious disease physiciansUse of hydroxychloroquineUse of remdesivirNoninvasive mechanical ventilationUse of antiviralsCoronavirus disease 2019Series of teleconferencesPotential antiviral activityLopinavir-ritonavirCritical illnessDisease physiciansMost patientsSupportive careMembrane oxygenationPediatric patientsAntiviral therapyMild courseSevere illnessIll childrenClinical trialsAGS Position Statement: Resource Allocation Strategies and Age‐Related Considerations in the COVID‐19 Era and Beyond
Farrell TW, Ferrante LE, Brown T, Francis L, Widera E, Rhodes R, Rosen T, Hwang U, Witt LJ, Thothala N, Liu SW, Vitale CA, Braun UK, Stephens C, Saliba D. AGS Position Statement: Resource Allocation Strategies and Age‐Related Considerations in the COVID‐19 Era and Beyond. Journal Of The American Geriatrics Society 2020, 68: 1136-1142. PMID: 32374440, PMCID: PMC7267615, DOI: 10.1111/jgs.16537.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAmerican Geriatrics SocietyOlder adultsAppropriate advance care planningShort-term outcomesRelevant clinical factorsCoronavirus disease 2019Advance care planningPotential short-term outcomeClinical factorsSevere illnessAdvanced ageDisease 2019Care planningMortality riskGeriatrics SocietySocial determinantsHealthcare professionalsHealth systemOlder peopleInterprofessional expertsEthics CommitteeCOVID-19 eraLife expectancyAgeCOVID-19Influence of Rainfall on Leptospira Infection and Disease in a Tropical Urban Setting, Brazil - Volume 26, Number 2—February 2020 - Emerging Infectious Diseases journal - CDC
Hacker KP, Sacramento GA, Cruz JS, de Oliveira D, Nery N, Lindow JC, Carvalho M, Hagan J, Diggle PJ, Begon M, Reis MG, Wunder EA, Ko AI, Costa F. Influence of Rainfall on Leptospira Infection and Disease in a Tropical Urban Setting, Brazil - Volume 26, Number 2—February 2020 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2020, 26: 311-314. PMID: 31961288, PMCID: PMC6986844, DOI: 10.3201/eid2602.190102.Peer-Reviewed Original Research
2018
Epidemiology of Lower Extremity Deep Venous Thrombosis in Critically Ill Adolescents
Faustino EVS, Shabanova V, Pinto MG, Li S, Trakas E, Miksa M, Gertz S, Polikoff LA, Napolitano M, Brudnicki AR, Tala JA, Silva CT, Investigators T, Miksa M, Taragin B, Blickman J, Taillie E, Trakas E, Balasco A, Herliczek T, Polikoff L, Dovi G, Napolitano M, Gertz S, Riordan M, Zasa J, Brudnicki A, Eldridge P, Li S, Pinto M, Faustino E, Silva C, Tala J. Epidemiology of Lower Extremity Deep Venous Thrombosis in Critically Ill Adolescents. The Journal Of Pediatrics 2018, 201: 176-183.e2. PMID: 29891258, DOI: 10.1016/j.jpeds.2018.05.006.Peer-Reviewed Original ResearchConceptsDeep venous thrombosisExtremity deep venous thrombosisIll adolescentsVenous thrombosisFrequency of DVTLower extremity deep venous thrombosisCases of DVTBilateral deep venous thrombosisPediatric intensive care unitInvasive mechanical ventilationCentral venous catheterizationIntensive care unitPharmacologic prophylaxisTherapeutic anticoagulationCohort studyPulmonary embolismCardiopulmonary supportCare unitMechanical ventilationVenous catheterizationSevere illnessSerial sonogramsLower extremitiesEpidemiologyThrombosis
2017
Engagement in Advance Care Planning and Surrogates’ Knowledge of Patients’ Treatment Goals
Fried TR, Zenoni M, Iannone L, O'Leary J, Fenton BT. Engagement in Advance Care Planning and Surrogates’ Knowledge of Patients’ Treatment Goals. Journal Of The American Geriatrics Society 2017, 65: 1712-1718. PMID: 28317097, PMCID: PMC5555783, DOI: 10.1111/jgs.14858.Peer-Reviewed Original ResearchConceptsAdvance care planningQuantity of lifeTreatment goalsSurrogate knowledgeCare planningVeterans Affairs Medical CenterPatients' treatment goalsCohort study SETTINGKnowledge of patientsCommunity-dwelling veteransHealth care proxyLife-sustaining treatmentSurrogates' perspectivesMultivariable analysisPrimary careSevere illnessMedical CenterSevere physical disabilitiesVeterans' ratingsACP engagementProxy completionStudy settingPhysical disabilitySurrogate reportsSizeable proportion
2016
Transfusion-transmitted babesiosis
Levin AE, Krause PJ. Transfusion-transmitted babesiosis. Current Opinion In Hematology 2016, 23: 573-580. PMID: 27537475, PMCID: PMC5241272, DOI: 10.1097/moh.0000000000000287.Peer-Reviewed Original ResearchConceptsTransfusion-transmitted babesiosisBlood donorsB. microti antibodiesInfectious blood donorsAssociated mortality rateOptimal screening strategyTransfusion-transmitted pathogensSignificant health burdenAvailable screening toolsUnited States populationPathogen inactivation methodsMicroti antibodiesSevere illnessHealth burdenMortality rateUS FoodDrug AdministrationBabesia microtiScreening toolLaboratory screeningScreening strategyBabesiosisInactivation methodPCR assaysRecent studies
2014
Hyperglycemia, Dysglycemia and Glycemic Control in Pediatric Critical Care
Agus M, Faustino E, Rigby M. Hyperglycemia, Dysglycemia and Glycemic Control in Pediatric Critical Care. 2014, 93-101. DOI: 10.1007/978-1-4471-6416-6_8.Peer-Reviewed Original ResearchGlycemic controlPediatric practitionersPoor outcomeProspective studyOrgan support measuresPediatric-specific dataPediatric-specific protocolsMore definitive dataHigher illness severityPediatric critical careInternational consensus statementProspective trialGlycemic managementIll patientsPediatric ICUIllness severityHigh morbidityHypoglycemic ratePatient populationPediatric intensivistsPediatric studiesSevere illnessIll childrenConsensus statementCritical care
2002
Role of mood stabilizers in bipolar disorder
Bhagwagar Z, Goodwin G. Role of mood stabilizers in bipolar disorder. Expert Review Of Neurotherapeutics 2002, 2: 239-248. PMID: 19811005, DOI: 10.1586/14737175.2.2.239.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply